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Background: Breast lymphoma (BL) is a rare entity. Although mimicking clinical presentation and 
radiological features of epithelial breast malignancies, prognosis and treatment management are different. 
Here we report our single institution experience in such population.
Methods: The database of our pathology institute was retrospectively searched for breast neoplasms coded 
as lymphoma from January 2000 to January 2017. The assessed data were: gender, age at diagnosis, laterality, 
stage (primary or secondary), histopathological diagnosis and grading (high vs. low) treatment, recurrence 
and survival status. Progression-free survival (PFS), overall survival (OS) and 5-year recurrence rate were 
estimated. An exploratory analysis comparing survival (PFS, OS and 5-year recurrence rate) between high- 
and low-grade histotypes and primary and secondary stages was performed.
Results: Fifteen patients were included in the analysis. All patients were affected by B-cell type lymphomas; 
the most frequent subtype was diffuse large B-cell lymphoma (DLBCL). Patients affected by high-grade 
lymphomas were treated with polychemotherapy followed in about half of cases by consolidative ipsilateral 
breast radiotherapy. Patients affected by low-grade lymphomas were treated with local treatment only (surgical 
resection +/− radiotherapy). No patient received radical surgery or axillary dissection. At a median follow 
up of 9 years, four patients had relapsed (all affected by high-grade lymphomas) with central nervous system 
(CNS) involved in half cases. Both median PFS and OS were not reached, but a slight trend toward a better 
survival was noticed in favor of primary breast lymphoma (PBL), while a clearer survival benefit was observed 
in the low-grade cohort. The estimated 5-year survival rate was 77% within the whole population, 78% vs. 
66% for primary vs. secondary and 100% vs. 66% for low-grade vs. high-grade BL.
Conclusions: Our data concerning clinical and pathological features are consistent with those previously 
reported. Management of disease was based on histology. Although being a rare disease it is mandatory to 
take it into account for differential diagnosis since treatment and prognosis differs widely from primary 
breast malignancies.
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Introduction
Breast lymphoma (BL) is a rare form of extranodal 
lymphoma (ENL) (1). It accounts for 1.7–2.2% of ENL (2) 
and represents 0.4–0.5% of breast malignancies (3-7), while 
being overall the most common extramammary cancer 
involving the breast (8,9). BLs have been categorized 
into primary breast lymphoma (PBL) and secondary 
breast lymphoma (SBL) types (10). BLs are classified as 
PBLs according to the criteria described by Wiseman 
and Liao (11) and modified by Hugh et al. (12), which 
include: presence of closely associated mammary tissue 
and lymphomatous infiltrate in an adequate specimen 
for pathologic evaluation, no previous diagnosis of 
extramammary lymphoma and lack of synchronous 
widespread disease other than simultaneous ipsilateral 
axillary nodes. SBLs are defined by the presence of secondary 
involvement of breast tissue by a concurrent or previous 
systemic lymphoma. SBLs are more frequent than PBLs. 
Clinical presentation and radiological findings of BLs 
are non-specific and mimic those of primary breast cancer 
(BC) (13,14). Therefore, differential diagnosis relies on 
pathological examination and biopsy is mandatory (15). 
Staging is based on 18F-FDG CT-PET and brain MRI in 
case of neurological symptoms (16). PBLs behave similarly 
to nodal lymphomas (NLs) harboring the same stage 
and histology, notably in the rituximab era no significant 
difference in clinical outcomes is detected between PBL and 
NL (17). Instead, outcomes of PBL are worse compared to 
those of epithelial BC. Indeed, for PBL the 5-year survival 
rate and recurrence rate are 40–80% and 15% respectively, 
whilst for BC the survival rate and recurrence rate at 
10 years are 89% and 12% respectively (18). Moreover, 
treatment of BL differs much form that of BC. Thus, 
it is crucial to secure an early and accurate histological 
diagnosis in order to select the best management and avoid 
mistreatment, including potentially harmful surgeries. 
We conducted a retrospective observational study with 
the aim to report prevalence, features and management of 
BLs at our institution. 
Methods
This is a retrospective observational study. The pathology 
database of our institute (Fondazione Policl inico 
Universitario Agostino Gemelli) was used to identify all 
breast neoplasms coded as lymphoma diagnosed from 
January 2000 to January 2017. Both primary and secondary 
BL were included. Each case was retrospectively reviewed 
by an experienced pathologist with the aim of confirming 
whether the neoplasm was correctly coded. Baseline 
demographic information and clinical follow-up data 
were collected from review of electronic medical charts; 
pathological features were retrieved from histological 
reports. The assessed data are the following: gender, 
age at diagnosis, laterality, stage (primary or secondary), 
histopathological diagnosis and grading (high vs. low) 
according to WHO nomenclature (19), treatment, 
recurrence and survival status. Progression-free survival 
(PFS) was defined as the time from the start of the 
treatment to the date of the first documented progression 
disease or death due to any cause, whichever occurred first. 
Overall survival (OS), was defined as the time from the 
start of the treatment to the date of death due to disease, 
or censored at the date of last follow-up for alive patients. 
Recurrence rate at 5-year was calculated. The Kaplan-
Meier method was used to estimate OS, PFS and 5-year 
recurrence rate. An exploratory analysis comparing survival 
(PFS, OS and 5-year recurrence rate) between high- and 
low-grade histotypes and primary and secondary stages was 
performed. Data were analyzed using IBM SPSS Statistics 
version 22 software.
Statement of ethics approval
This is a retrospective and observational study and no 
approval by the Ethics Committee is required. Each patient 
was treated as well as in clinical practice. All patients at 
the time of surgery and the onset of chemotherapy have 
signed an informed consent, authorizing the use of their 
anonymized data for scientific purposes.
Results
Within the study period,  15 samples were coded 
as lymphomas and were included in the analysis . 
Demographics and baseline characteristics of study 
population are summarized in Table 1. Females were 
affected more frequently compared with males, 13 (87%) 
vs. 2 (13%) respectively. The median age at diagnosis was 
64 years (range, 10–82 years). All patients presented with 
a solitary mass, occurring in 7 cases within the left breast 
(47%) and in 8 cases (53%) within the right breast; no case 
of bilateral involvement was reported. According to the 
criteria by Wiseman and Liao, 10 cases were classified as 
PBL (67%) and 5 cases as SBL (33%). All neoplasms were 
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B-cell type lymphomas. Diffuse large B-cell lymphoma 
(DLBCL) was the most frequent type with 8 cases (53%); 
of those 6 cases were classified as PBL and 2 cases as SBL. 
Rarer histological types were the following: marginal zone 
lymphoma (2 cases, 13%, classified as PBL), plasmablastic 
lymphoma (2 cases, 13%, one classified as PBL and one as 
SBL), follicular lymphoma (1 case, 7%, classified as PBL), 
Burkitt lymphoma (1 case, 7%, classified as SBL) and B-cell 
lymphoblastic lymphoma (1 case, 7%, classified as SBL). 
Given such classification, only 3 cases (2 marginal zone 
lymphomas and 1 follicular lymphoma) accounting for 20% 
were low-grade BL (Figure 1), the remaining 12 samples 
were high-grade BL (Figure 2).
Diagnosis was obtained in each case with a sequence 
of fine-needle aspiration, which posed the cytological 
suspect of lymphoproliferative disease, followed by 
excisional biopsy, which allowed a histological confirmation. 
Once achieved a clear histopathological classification, 
all patient underwent computed tomography scan of 
the chest, abdomen and pelvis (more recently 18F-FDG 
CT-PET scan) and bone marrow biopsy, in order to allow 
a correct staging. Treatment was established according to 
both staging and histology. Patients affected by DLBCL 
received anthracycline-based chemotherapy and rituximab 
followed in half of cases by consolidative ipsilateral breast 
radiotherapy. The chemotherapy regimen included 
cyclophosphamide, doxorubicin, vincristine and prednisone 
(CHOP), combined with rituximab. Patients affected by 
plasmablastic lymphomas, Burkitt lymphoma and B-cell 
lymphoblastic lymphoma were treated accordingly to 
diagnosis with polychemotherapy. Patients affected by 
marginal zone and follicular lymphomas did not receive 
chemotherapy, undergoing instead to surgical resection; 
of those one patient received consolidative ipsilateral 
radiotherapy due to presence of positive surgical margins. 
No patient underwent to radical surgery or axillary 
dissection.
At a median follow up of 9 years (range, 0.7–17 years), 
four patients had relapsed, all of those were affected by high 
grade BL. Central nervous system (CNS) was the site of 
progression in two cases. Patients who presented relapse 
subsequently died due to malignancy. Moreover, during 
the follow up period one patient died due to concomitant 
disease. Median PFS and OS have not been reached both 
in the whole population (Figure 3A,B, respectively) and in 
the exploratory analysis according to primary vs. secondary 
stage (Figure 4A,B, respectively) and to high- vs. low-grade 
histotype (Figure 5A,B, respectively). Indeed, only five 
patients were not censored at the time of analysis. However, 
a slight trend toward a better survival was noticed in favor 
of PBL compared with SBL (Figure 4A,B), while a clearer 
survival benefit was observed in the low-grade cohort (Figure 
5A,B). The estimated 5-year survival rate was 77% within 
the whole population, 78% vs. 66% for PBL vs. SLB and 
100% vs. 66% for low- vs. high-grade BL. 
Discussion
BL is an extremely rare disease. Evidences concerning 
this entity rely mainly on case reports and case series 
rather than clinical trials and indicate that both diagnosis 
and management are difficult. Indeed, while clinical 
presentation and radiological features mimic those of 
Table 1 Patients’ characteristics
Characteristics Data
Age, years
Median 64
Range 10–82
Gender, n [%]
Male 2 [13]
Female 13 [87]
Primary side, n [%]
Left breast 7 [47]
Right breast 8 [53]
Type, n [%]
PBL 10 [67]
SBL 5 [33]
Histology, n [%]
B-cell lymphoma 15 [100]§
DLBCL 8 [53]§
MZL 2 [13]*
Plasmablastic 2 [13]§
Follicular 1 [7]*
Burkitt 1 [7]§
Linfoblastic 1 [7]§
§, high-grade lymphoma; *, low-grade lymphoma. PBL, primary 
breast lymphoma; SBL, secondary breast lymphoma; DLBCL, 
diffuse large B-cell lymphoma; MZL, marginal zone lymphoma.
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Figure 1 Marginal zone breast lymphoma: morphological and immunohistochemical findings in a low-grade lymphoma. (A) Breast 
parenchyma showed a diffuse infiltrate of morphologically heterogeneous small B cells (marginal zone or centrocyte-like cells, monocytoid 
like cells, small lymphocytes and centroblast-like cells (Haematoxylin and Eosin, ×4); (B) the neoplastic population was composed of the 
characteristic marginal zone B-cells with small-medium sized nuclei with only moderately dispersed chromatin and inconspicuous nucleoli. 
Larger cells with a centroblastic appearance were present, but they were in the minority (Haematoxylin and Eosin, ×10). The marginal neoplastic 
cells showed positive immunostaining for CD20 (C, LSAB-HRP, ×4) and Bcl2 (D, LSAB-HRP, ×4), negativity for Bcl6 (E, LSAB-HRP, ×4) and 
CyclinD1 (F, LSAB-HRP, ×10). The proliferative index in the marginal component has been valued as 10% (G, LSAB-HRP, ×40).
A B
C D
E
G
F
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epithelial BC, prognosis and treatment are quite different 
(13,14). Therefore, it should be considered in differential 
diagnosis in order to guarantee a correct treatment. 
Diagnosis relies on suspect posed by fine-needle cytology 
and must be confirmed by histology (18).
Here we report our single-institution experience in 
this specific patients’ population. Demographics and 
clinicopathological features of our patients are in accordance 
with previously reported evidences. In fact, BL can develop 
in both gender, but occur more frequently among women 
(98%) (5,15,20-27) and most cases present in the 5th or 6th 
decade of life (3,28). The predominant presenting sign is 
a painless solitary mass (26) involving mainly the external 
superior quadrant of the right breast (29,30), although 
bilateral involvement has been reported in 1–14% of cases 
(31,32). Signs of nipple or skin involvement are infrequent 
(14,15,20) and constitutional B symptoms (such as fever, 
night sweats and weight loss) are rare and usually indicative 
of disseminated disease (5,21,25-27,33). Histologically, the 
majority of BL are non-Hodgkin’s B-cell lymphomas and 
the most frequent subtype is DLBCL (10,34) (56–84%), 
followed by marginal zone (9–28%), follicular (10–19%) 
Figure 2 Diffuse B-cell lymphoma: morphological and immunohistochemical findings in a high-grade lymphoma. (A) Diffuse, massive 
infiltration of neoplastic large B cells in the superficial dermis with extension to the hypodermic tissue. No evidence of epidermotropism 
(Haematoxylin and Eosin, ×4); (B) the lymphoid infiltrate were composed of centroblastic-like and immunoblastic-like B cells. They 
appeared medium-large sized with oval to round vesicular nuclei and very scant cytoplasm (Haematoxylin and Eosin, ×10); (C) a 
higher magnification of the neoplastic lymphoid population (Haematoxylin and Eosin, ×40); (D,E) the neoplastic cells showed positive 
immunostaining for CD20 (LSAB-HRP, ×40). Note the high proliferative index (LSAB-HRP, ×40).
A
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and Burkitt lymphoma (<6%) (16). 
In accordance with available data, treatment of our 
population was based upon histological subtype, disease 
staging and patients’ clinical features and comorbidities. A 
clear difference in prognosis and management of high- and 
low-grade BL can be observed. Treatment strategies for 
high-grade BL comprise a combination of anthracycline-
based  chemotherapy  and  r i tux imab fo l lowed by 
consolidative ipsilateral breast radiotherapy, which reduce 
the risk of local recurrence (6,21,33,35). R-CHOP is the 
standard regimen for patients affected by DLBCL. Surgical 
interventions, preferably minimally-invasive, should be 
limited to biopsy to obtain the correct histological diagnosis 
and guide therapy. Whereas surgeries beyond excisional 
biopsy should be avoided since radical mastectomy and 
axillary dissection did not show to add any benefit in the 
treatment of PBL (5,25,31,36), being even detrimental. 
Low-grade BLs do not need chemotherapy, instead should 
be treated with surgical excision followed by radiotherapy 
in case of positive margins. 
Figure 3 Survival in the whole population. (A) PFS of the whole population; (B) OS of the whole population. PFS, progression-free survival; 
OS, overall survival.
Figure 4 Survival in PBLs vs. SBLs. (A) PFS of PBLs compared with SBLs; (B) OS of PBLs compared with SBLs. PFS, progression-free 
survival; PBL, primary breast lymphoma; SBL, secondary breast lymphoma; OS, overall survival.
100
80
60
40
20
0
P
ro
ba
bi
lit
y 
of
 s
ur
vi
va
l (
%
)
0                50             100              150            200
Time (months)
Progression free survival
Not censored
Censored
A Not censored
Censored
Overall survival
0                50             100             150            200
Time (months)
100
80
60
40
20
0
P
ro
ba
bi
lit
y 
of
 s
ur
vi
va
l (
%
)
B
100
80
60
40
20
0
P
ro
ba
bi
lit
y 
of
 s
ur
vi
va
l (
%
)
Progression free survival
0                 50              100              150             200
Time (months)
Censored
PBL
SBL
PBL vs. SBL
Censored
A
100
80
60
40
20
0
P
ro
ba
bi
lit
y 
of
 s
ur
vi
va
l (
%
)
Overall survival
0                 50              100              150             200
Time (months)
Censored
PBL
SBL
PBL vs. SBL
Censored
B
S278 Orlandi et al. BL: a single-institution retrospective analysis
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2018;7(Suppl 3):S272-S280 tcr.amegroups.com
Concerning the recurrence rate, our analysis is 
consistent with available data. Indeed, we reported a 5-year 
survival rate of 77% in the whole population, which is 
in accordance with 40–80% rate previously showed (18). 
Moreover, relapses occurred in half cases within CNS. 
This is concordant with previous studies, where, despite 
administration of optimal treatment, extranodal progression 
has frequently been reported, involving mainly CNS 
and breast (17,37-39). Thus, given the high risk of CNS 
recurrence and the poor prognosis after such event, some 
authors hypothesized the inclusion of CNS-directed 
prophylaxis in the initial management of specific high-grade 
BLs (21,40,41).
Despite median PFS and OS were not reached, a slight 
trend toward a better survival was noticed in favor of 
PBL vs. SBL and a clearer survival benefit was observed 
in the low-grade vs. high-grade cohort. Moreover, all 
patients whose disease recurred were affected by high-
grade histotypes. Thus, our data corroborate the evidence 
that low-grade BLs display an indolent trend and allow 
hypothesizing that PBLs present a better prognosis 
compared with SBLs. 
Clearly our analysis has a number of limitations. Firstly, 
the evaluation is limited by the selection bias connected to 
its retrospective nature and to the small sample size of our 
cohort, given the rarity of the disease. However, due to the 
scarcity of the disease it would be difficult to assemble a 
prospective analysis. Secondly, a lack of uniform approach 
is noted given the heterogeneous population and the long 
interval of observation. 
Given the importance of achieving a correct histological 
diagnosis, it is crucial to stress the key role played by the 
pathologist in posing the suspect according to cytological 
features of fine needle aspiration and subsequently 
characterizing the histologic sample. In this light, it is 
important to note that we did not observe discrepancies 
between cytology suspect and histology confirmation, 
this is probably due to the high expertise of our dedicated 
breast pathologists. Moreover, multidisciplinary discussion 
involving clinicians, surgeons and pathologists is critical in 
order to define the correct treatment management, avoiding 
unnecessary and potentially detrimental surgeries. 
Conclusions
Our results are in accordance with previously reported 
evidences concerning epidemiology, clinicopathological 
features and management of BLs. Although being a rare 
disease, BLs must be taken into account in differential 
diagnosis of breast neoplasms since treatment and 
prognosis are quite different. Therefore, histological 
characterization is crucial in order to guarantee a tailored 
management. Indeed, high-grade BLs should receive a 
combination of chemotherapy and involved-field radiation 
therapy, whereas low-grade BLs require loco-regional 
treatment only.
Figure 5 Survival in high-grade vs. low-grade BLs. (A) PFS of high-grade BLs compared with low-grade BLs; (B) OS of high-grade BLs 
compared with low-grade BLs. PFS, progression-free survival; BL, breast lymphoma; OS, overall survival.
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